Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Regeneron Pharmaceuticals



) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.0%. By the end of trading, Regeneron Pharmaceuticals rose $4.47 (1.8%) to $252.18 on light volume. Throughout the day, 430,196 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 1,123,500 shares. The stock ranged in a price between $246.69-$253.42 after having opened the day at $248.51 as compared to the previous trading day's close of $247.71. Other companies within the Drugs industry that increased today were:




), up 14.6%,




), up 13.3%,

Catalyst Pharmaceutical Partners



), up 13.3% and

Regulus Therapeutics



), up 12.1%.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $24.1 billion and is part of the health care sector. The company has a P/E ratio of 33.3, above the S&P 500 P/E ratio of 17.7. Shares are up 47.0% year to date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates

Regeneron Pharmaceuticals

as a


. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and compelling growth in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front,

ARCA biopharma



), down 30.9%,




), down 12.1%,

TG Therapeutics



), down 11.3% and




), down 7.9% , were all laggards within the drugs industry with

Ariad Pharmaceuticals



) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.